IRD Stock Catalyst: Opus Genetics Announces Favorable Safety Profile in Low-Dose Cohort 1 of BIRD-1 Trial

Sep 9, 2026 · 7:42am ET

No serious adverse events or dose-limiting toxicities observed.

Max move

+53.4%

High of day $7.07

Sparker timei

7:42am ET

IRD · Sep 9, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Opus Genetics, Inc. (Nasdaq: IRD) announced on September 9, 2026, the results from Low-Dose Cohort 1 of the BIRD-1 trial, an ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1. The trial showed a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed.

The announcement was made via an EDGAR Filing and accompanied by an earnings transcript featuring management and Key Opinion Leader and retinal specialist, Mark Pennesi, M.D., PhD.

As of the latest data, Opus Genetics has a free float of 34,978,921 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time IRD sparks.

Download Sniper App →

Catch the next IRD-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →